Brind.

Analyst firm upgraded price objective on 10X Genomics stock.

1 report, 1 independent Updated Sep 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Leerink partners 10X Genomics

Keep exploring

The entities involved

Leerink partners
U.S. investment bank
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
- A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38
10X Genomics
American biotechnology company

Nothing else this week.

Related events

Truist Financial and Leerink Partners raised price objectives for Eli Lilly and Company stock.Sep 2

Coverage

Newest first; wire copies grouped

Sep 11themarketsdaily.com